Revenue Breakdown
Composition ()
No data
Revenue Streams
Fortress Biotech Inc (FBIO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Journey, accounting for 91.4% of total sales, equivalent to $15.01M. Another important revenue stream is Avenue. Understanding this composition is critical for investors evaluating how FBIO navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Fortress Biotech Inc maintains a gross margin of 61.32%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -38.63%, while the net margin is 50.07%. These profitability ratios, combined with a Return on Equity (ROE) of -13.86%, provide a clear picture of how effectively FBIO converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, FBIO competes directly with industry leaders such as TTRX and CTOR. With a market capitalization of $102.43M, it holds a significant position in the sector. When comparing efficiency, FBIO's gross margin of 61.32% stands against TTRX's N/A and CTOR's 79.99%. Such benchmarking helps identify whether Fortress Biotech Inc is trading at a premium or discount relative to its financial performance.
